1. Home
  2. HCM
  3. HCM News

Latest HUTCHMED (China) Limited (HCM) News on November 17, 2024

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

GlobeNewswire

a month ago

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

Spire Declares Dividend

PR Newswire

10 months ago

Spire Declares Dividend

Share on Social Networks: